ACT Brief: Multimodal AI Systems Architecture, Trust-Based Trial Recruitment, and Big Pharma AI Transformation

This is the Applied Clinical Trials Brief—your fast track to the latest insights shaping clinical operations and drug development.

• In a new contributed article, Partha Anbil examined how AI-enabled systems medicine is moving from isolated clinical pilots to unified multimodal architectures integrating genomics, imaging, vital signs, and clinical narratives. For biopharma, this convergence could reshape patient segmentation, biomarker validation, trial design, site selection, and post-launch evidence generation—but only when organizations build governance and validation into deployment rather than treating AI as disconnected technology projects.
• In another contributed article, Del Smith and Cherish Boxall discussed why enrollment decisions hinge on trust, hope, and fear rather than clinical eligibility alone, requiring relationship-based community engagement paired with behavioral readiness assessment. Traditional education-centric outreach addresses cognitive trust but fails against affective barriers unless reinforced by trusted intermediaries—clinicians, family members, faith leaders, and advocacy organizations—who validate credibility and safety.
• In a Pharmaceutical Executive podcast, Emmanuel Frenehard, executive vice president and chief digital officer at Sanofi, discussed scaling AI across a global enterprise through concentrated strategic bets rather than scattered pilots. Sanofi's three-tiered AI strategy—snackable, specialized, and generative—focuses on reinventing workflows rather than simply automating them, supported by governance frameworks, workforce upskilling, and human-in-the-loop oversight that prioritize patient outcomes alongside operational transformation.

That's all for today's ACT Brief. Join us tomorrow for more updates shaping clinical operations and drug development. Thanks for listening.